A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications
Seasonal influenza is responsible for many hospitalizations and deaths each year, despite effective antiviral treatments. Some individuals have medical conditions such as heart or lung diseases that make them particularly at risk of severe influenza infections that may result in hospitalization or death. Oseltamivir (Tamiflu) is used most often to treat flu, but there are still many hospitalizations, complications, and deaths even with treatment. This study evaluated the use of combination antivirals (amantadine, oseltamivir, and ribavirin) compared to oseltamivir alone in the treatment of influenza in an at-risk population.
Indication: Influenza
Modality: small molecule
Target: Amantadine, Ribavirin, Oseltamivir, Oseltamivir
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Source URL: ClinicalTrials.gov
Source updated: Feb 04, 2019
Ingested: Jun 08, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Amantadine, Ribavirin, Oseltamivir, Oseltamivir
View original source fields
Condition raw: Influenza
Condition normalized: Influenza
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Amantadine, Ribavirin, Oseltamivir, Oseltamivir
Target normalized: Amantadine, Ribavirin, Oseltamivir, Oseltamivir